Patents Assigned to Ansun Biopharma, Inc.
-
Patent number: 11697803Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.Type: GrantFiled: July 15, 2019Date of Patent: July 11, 2023Assignee: Ansun Biopharma, Inc.Inventor: Stephen Hawley
-
Patent number: 11241486Abstract: Methods and compositions for treating Middle East respiratory syndrome coronavirus (MERS-CoV) infection using polypeptides having sialidase activity are provided herein.Type: GrantFiled: January 27, 2020Date of Patent: February 8, 2022Assignee: Ansun Biopharma, Inc.Inventor: Ronald D. Moss
-
Publication number: 20200297822Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.Type: ApplicationFiled: June 4, 2020Publication date: September 24, 2020Applicant: Ansun Biopharma, Inc.Inventors: Fang Fang, David Wurtman, Ron Moss, Michael P. Malakhov
-
Patent number: 10583086Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.Type: GrantFiled: September 25, 2017Date of Patent: March 10, 2020Assignee: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Patent number: 10525109Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: GrantFiled: August 22, 2017Date of Patent: January 7, 2020Assignee: Ansun Biopharma, Inc.Inventors: Fang Fang, Michael P. Malakhov
-
Patent number: 10351828Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.Type: GrantFiled: March 14, 2014Date of Patent: July 16, 2019Assignee: Ansun Biopharma, Inc.Inventor: Stephen Hawley
-
Patent number: 10328128Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.Type: GrantFiled: September 17, 2015Date of Patent: June 25, 2019Assignee: Ansun Biopharma, Inc.Inventor: Ronald B. Moss
-
Patent number: 10300116Abstract: The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen.Type: GrantFiled: June 10, 2014Date of Patent: May 28, 2019Assignee: Ansun Biopharma, Inc.Inventor: Ronald D. Moss
-
Publication number: 20180140683Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.Type: ApplicationFiled: January 8, 2018Publication date: May 24, 2018Applicant: Ansun Biopharma, Inc.Inventors: Fang Fang, David Wurtman, Ron Moss, Michael P. Malakhov
-
Patent number: 9764007Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: GrantFiled: November 30, 2015Date of Patent: September 19, 2017Assignee: Ansun Biopharma, Inc.Inventors: Fang Fang, Michael P. Malakhov
-
Patent number: 9700602Abstract: Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.Type: GrantFiled: May 16, 2016Date of Patent: July 11, 2017Assignee: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Tiejun Li
-
Publication number: 20160120961Abstract: The present disclosure provides novel compositions and methods for treating an infection of the skin resulting from an infection of a member of the Orthopolyomavirus virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus. The present disclosure also comprises therapeutic compositions having sialidase activity, including protein based compounds having sialidase catalytic domains. Compounds of the disclosure can be used for treating pathogenic infection to the skin.Type: ApplicationFiled: June 10, 2014Publication date: May 5, 2016Applicant: ANSUN BIOPHARMA, INC.Inventor: Ronald D. Moss
-
Patent number: 9212353Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: GrantFiled: May 12, 2014Date of Patent: December 15, 2015Assignee: Ansun Biopharma, Inc.Inventors: Fang Fang, Michael Malakhov
-
Publication number: 20140342006Abstract: A method for preparing a microparticle suspension, which comprises: (a) providing protein microparticles having a median diameter between 5 and 13 microns and a GSD less than 2.5; (b) combining the microparticles with a liquid, pharmaceutically acceptable, water miscible media to create a first mixture; (c) adding an aqueous media to the first mixture to create second mixture; and (d) mixing the second mixture to create a microparticle suspension is described. The suspension are injectable even when they contain a relatively high concentration of protein.Type: ApplicationFiled: March 13, 2014Publication date: November 20, 2014Applicant: Ansun Biopharma, Inc.Inventor: Tiejun Li
-
Publication number: 20140328820Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: ApplicationFiled: May 12, 2014Publication date: November 6, 2014Applicant: Ansun Biopharma, Inc.Inventors: Fang Fang, Michael Malakhov
-
Publication number: 20140308729Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.Type: ApplicationFiled: March 14, 2014Publication date: October 16, 2014Applicant: Ansun Biopharma, Inc.Inventor: Stephen Hawley
-
Publication number: 20140134150Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.Type: ApplicationFiled: January 6, 2014Publication date: May 15, 2014Applicant: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Patent number: 8722869Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: GrantFiled: August 19, 2013Date of Patent: May 13, 2014Assignee: Ansun Biopharma, Inc.Inventors: Fang Fang, Michael P. Malakhov
-
Publication number: 20140099696Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: April 30, 2013Publication date: April 10, 2014Applicant: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang
-
Patent number: 8623419Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.Type: GrantFiled: November 4, 2011Date of Patent: January 7, 2014Assignee: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Fang Fang